Responses at places like ASCO are a "fast money" phenomenon.
And it looks like CLVS was the ticket-particularly ironic since much of their rise is related to results in egfr NSCLC that appear to eat our (imagined) lunch on that score.
Therefore, when you put together what looks like solid preliminary CLVS results in such an important indication, together with no clarity when some was hoped for(from Ariad), obviously, the fast money shift(particularly with this relatively modest volume) explains today's dynamic.
However, what we(as long-term Ariad investors) need to remember, is that this is probably a very short term event, in view of all the other shots on goal in Ariad's arsenal.
Hard to swallow, but recoverable over time...
